| From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer C Nevala-Plagemann, M Hidalgo, I Garrido-Laguna Nature reviews Clinical oncology 17 (2), 108-123, 2020 | 293 | 2020 |
| Placenta-based therapies for the treatment of epidermolysis bullosa C Nevala-Plagemann, C Lee, J Tolar Cytotherapy 17 (6), 786-795, 2015 | 26 | 2015 |
| Clinical activity of selitrectinib in a patient with mammary analogue secretory carcinoma of the parotid gland with secondary resistance to entrectinib V Florou, C Nevala-Plagemann, J Whisenant, P Maeda, GW Gilcrease, ... Journal of the National Comprehensive Cancer Network 19 (5), 478-482, 2021 | 21 | 2021 |
| Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma S Iyengar, C Nevala-Plagemann, I Garrido-Laguna Therapeutic advances in medical oncology 13, 17588359211045861, 2021 | 13 | 2021 |
| Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy C Nevala-Plagemann, S Francis, C Cavalieri, R Tao, J Whisenant, ... ESMO open 3 (5), e000386, 2018 | 13 | 2018 |
| A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States C Nevala-Plagemann, S Sama, J Ying, J Shen, B Haaland, V Florou, ... Journal of the National Comprehensive Cancer Network 21 (3), 257-264, 2023 | 7* | 2023 |
| Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study L Miotke, C Nevala-Plagemann, J Ying, V Florou, B Haaland, ... BMC cancer 22 (1), 1-8, 2022 | 6* | 2022 |
| Real-world outcomes of patients with BRAF-mutated metastatic colorectal cancer treated in the United States A Trunk, M Braithwaite, C Nevala-Plagemann, L Pappas, B Haaland, ... Journal of the National Comprehensive Cancer Network 20 (2), 144-150, 2022 | 6* | 2022 |
| Treatment trends and clinical outcomes of left-sided RAS/RAF wild-type metastatic colorectal cancer in the United States C Nevala-Plagemann, S Iyengar, AD Trunk, L Pappas, B Haaland, ... Journal of the National Comprehensive Cancer Network 20 (3), 268-275, 2022 | 4 | 2022 |
| Emerging treatment strategies in pancreatic cancer A Trunk, L Miotke, C Nevala-Plagemann, H Verdaguer, T Macarulla, ... Pancreas 50 (6), 773-787, 2021 | 4 | 2021 |
| Late-Holocene climate changes linked to ecosystem shifts in the Northwest Wisconsin Sand Plain, USA R Calcote, C Nevala-Plagemann, EA Lynch, SC Hotchkiss The Holocene 31 (3), 409-420, 2021 | 4 | 2021 |
| Comparative genomic analysis of pancreatic acinar cell carcinoma (PACC) and pancreatic ductal adenocarcinoma (PDAC) unveils new actionable genomic aberrations in PACC V Florou, A Elliott, MH Bailey, D Stone, K Affolter, HP Soares, ... Clinical cancer research 29 (17), 3408-3417, 2023 | 3 | 2023 |
| Real-world outcomes with front-line doublet versus triplet chemotherapy in advanced gastroesophageal adenocarcinoma. S Sama, CD Nevala-Plagemann, J Smith, LM Pappas, B Haaland, ... Journal of Clinical Oncology 41 (4_suppl), 313-313, 2023 | 3 | 2023 |
| Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel+ Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma MK Baron, X Wang, C Nevala-Plagemann, JC Moser, B Haaland, ... Pancreas 50 (6), 796-802, 2021 | 3 | 2021 |
| Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front … C Nevala-Plagemann, J Moser, GW Gilcrease, I Garrido-Laguna ESMO open 4 (4), e000539, 2019 | 3* | 2019 |
| Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair–Deficient Pancreatic Cancer After Planned Treatment Interruption V Florou, C Nevala-Plagemann, KE Barber, JN Mastroianni, CC Cavalieri, ... JCO Precision Oncology 4, 2020 | 2 | 2020 |
| Pancreatic acinar carcinoma - a rare entity with a targetable BRAF V600E mutation V Florou, C Nevala-Plagemann, S Mulvihill, I Garrido-Laguna Cancer Research 80 (16_Supplement), 817-817, 2020 | 1 | 2020 |
| NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? C Nevala-Plagemann, I Garrido-Laguna Nature Reviews Clinical Oncology, 1-2, 2024 | | 2024 |
| Clinical impact of KRAS mutations in metastatic pancreatic ductal adenocarcinoma (PDAC). C Norton, J Smith, Z Rubnitz, GH Tan, CD Nevala-Plagemann, HP Soares, ... Journal of Clinical Oncology 42 (3_suppl), 619-619, 2024 | | 2024 |
| Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: case report JT Smith, S Sama, V Florou, C Nevala-Plagemann, I Garrido-Laguna Journal of Gastrointestinal Oncology 14 (6), 2637, 2023 | | 2023 |
Ignacio Garrido-LagunaProfessor, Division of Oncology, University of UtahVerified email at hci.utah.edu
